Neurobiological Technologies, Inc.
NTII
$0.00
$0.000.00%
OTC PK
12/17/2009 | 09/30/2009 | 06/30/2009 | 03/31/2009 | 12/31/2008 | |
---|---|---|---|---|---|
Revenue | -- | 69.03% | 363.45% | -18.21% | -4.70% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | 69.03% | 363.45% | -18.21% | -4.70% |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | 69.03% | 363.45% | -18.21% | -4.70% |
SG&A Expenses | -44.80% | -34.03% | -28.21% | -29.54% | -37.19% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | -94.28% | -87.06% | -86.38% | -65.01% | 24.28% |
Operating Income | 91.82% | 259.98% | 502.79% | 107.91% | -43.02% |
Income Before Tax | 93.56% | 299.17% | 509.79% | 91.49% | -13.87% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | 94.11% | 295.69% | 509.79% | 91.49% | -13.87% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 94.11% | 295.69% | 509.79% | 91.49% | -13.87% |
EBIT | 91.82% | 259.98% | 502.79% | 107.91% | -43.02% |
EBITDA | 91.83% | 262.89% | 508.81% | 108.60% | -43.55% |
EPS Basic | 94.13% | 295.61% | 513.09% | 91.49% | 18.32% |
Normalized Basic EPS | 92.08% | 287.67% | 547.13% | 106.82% | 18.32% |
EPS Diluted | 93.13% | 294.93% | 512.45% | 91.49% | 18.32% |
Normalized Diluted EPS | 92.08% | 287.52% | 547.13% | 106.82% | 18.32% |
Average Basic Shares Outstanding | 0.22% | 0.02% | -0.77% | 0.05% | 39.41% |
Average Diluted Shares Outstanding | 0.22% | 0.08% | -0.77% | 0.05% | 39.41% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |